Does Chewing Tobacco Affect Fatty Liver?

Does chewing tobacco affect fatty liver? Evidence suggests it does, and potentially in serious ways. Chewing tobacco delivers nicotine, heavy metals and potent carcinogens directly into the bloodstream, placing significant strain on a liver already under metabolic stress. For people living with metabolic dysfunction-associated steatotic liver disease (MASLD), formerly known as non-alcoholic fatty liver disease, smokeless tobacco use may accelerate progression from simple fat accumulation to more advanced inflammation and fibrosis. This article explains the biological mechanisms involved, what stopping tobacco use can do for liver recovery, and when to seek medical advice.

Does chewing tobacco make fatty liver disease worse?

Yes, chewing tobacco is associated with worsening fatty liver disease; it introduces nicotine, carcinogens and heavy metals that promote oxidative stress, inflammation and fat accumulation in the liver.

Yes, chewing tobacco is associated with worsening fatty liver disease, and current evidence suggests that smokeless tobacco products can accelerate liver injury in people who already have hepatic steatosis. Fatty liver disease is now termed metabolic dysfunction-associated steatotic liver disease (MASLD), replacing the older name non-alcoholic fatty liver disease (NAFLD).^[1][2] It occurs when excess fat accumulates in liver cells. While alcohol and poor diet are the most widely recognised drivers, tobacco use in all its forms, including smokeless varieties such as chewing tobacco, snus and snuff, introduces a range of toxic compounds that place additional strain on the liver.

Chewing tobacco delivers nicotine and a complex mixture of carcinogens, heavy metals and nitrosamines into the bloodstream via the oral mucosa.^[14] The liver is responsible for metabolising many of these substances, and repeated exposure can promote oxidative stress, inflammation and fat accumulation within hepatic tissue. Observational studies have found associations between smokeless tobacco use and elevated liver enzymes, which are markers of liver cell damage, though establishing direct causation is difficult because tobacco users often have other lifestyle risk factors.

It is important to note that much of the research in this area is observational. Nevertheless, no evidence suggests that chewing tobacco is safe for the liver, and several biological mechanisms provide a plausible basis for harm. People living with MASLD are generally advised to avoid all tobacco products as part of a broader strategy to reduce liver injury, in line with guidance from the British Liver Trust and NHS patient information on MASLD.

How smokeless tobacco damages the liver

Smokeless tobacco damages the liver through oxidative stress, systemic inflammation and the hepatotoxic effects of nicotine and tobacco-specific nitrosamines, which can accelerate progression from steatosis to steatohepatitis and fibrosis.

Smokeless tobacco damages the liver primarily through oxidative stress, systemic inflammation and the direct hepatotoxic effects of nicotine and tobacco-specific nitrosamines (TSNAs). When chewing tobacco is held in the mouth, nicotine and other chemicals are absorbed through the buccal mucosa into the systemic venous circulation, bypassing first-pass hepatic metabolism. The liver is subsequently exposed to these compounds via systemic blood flow rather than via the portal circulation, so the earlier description of a 'concentrated portal dose' does not apply; nonetheless, hepatic exposure is significant and repeated with every use.

Nicotine has been shown in laboratory and animal studies to promote hepatic lipid accumulation, impair mitochondrial function and increase the production of reactive oxygen species. These are preclinical findings and their direct translation to human disease requires further research, but they provide a plausible mechanistic basis for harm. Reactive oxygen species cause oxidative damage to liver cell membranes and DNA, triggering inflammatory pathways that can progress from simple steatosis to metabolic dysfunction-associated steatohepatitis (MASH, formerly called non-alcoholic steatohepatitis or NASH), a more serious form of the condition characterised by inflammation and cell death. TSNAs, which are among the most potent carcinogens in tobacco products and are classified as such by the International Agency for Research on Cancer (IARC), have also been linked to hepatocellular injury in preclinical models.

In addition, nicotine stimulates the release of catecholamines such as adrenaline, which can promote insulin resistance. Insulin resistance is a central driver of MASLD, as it encourages the liver to produce and retain more fat. Heavy metals found in tobacco, including cadmium and lead, are recognised hepatotoxins that can accumulate in liver tissue over time and further impair its function.^[5]

Collectively, these mechanisms mean that regular chewing tobacco use creates a hostile biochemical environment for a liver already under metabolic stress, potentially accelerating progression from early-stage fatty liver to more advanced fibrosis or cirrhosis. The evidence base for these mechanisms draws on preclinical data and observational human studies; large prospective trials in smokeless tobacco users are limited.

Can giving up chewing tobacco help your liver recover?

Stopping chewing tobacco can support liver recovery; quitting tobacco is associated with reduced liver enzyme levels and improved markers of hepatic inflammation, particularly in early-stage disease.

Stopping chewing tobacco can support liver recovery, and the liver has a remarkable capacity for regeneration when harmful exposures are removed. Research into smoking cessation and liver health consistently shows that quitting tobacco is associated with reductions in liver enzyme levels and improvements in markers of hepatic inflammation. Most of this evidence relates to cigarette smoking; evidence specific to smokeless tobacco cessation and liver outcomes is more limited, so the benefit is plausible but should be understood as an extrapolation from related data.

The timeline for liver improvement varies depending on the degree of existing damage. In early-stage MASLD, where significant fibrosis has not yet developed, lifestyle changes including stopping tobacco use, improving diet and increasing physical activity can lead to meaningful reductions in liver fat within weeks to months. In more advanced disease, recovery is slower and may be incomplete, but halting further injury remains clinically important.

Nicotine replacement therapy (NRT), such as patches, gum or lozenges, is available on the NHS. NICE NG92 (Stop smoking interventions and services) recommends NRT as a first-line pharmacological aid for tobacco dependence, and NICE PH39 (Smokeless tobacco: South Asian communities) provides guidance specific to smokeless tobacco cessation.^[11] Varenicline is a prescription medicine with good evidence for smoking cessation and is also used in smokeless tobacco cessation; bupropion is licensed for smoking cessation in the UK but evidence for its use specifically in smokeless tobacco cessation is more limited, and a prescriber can advise on suitability.^[13][12] A Cochrane review of interventions for smokeless tobacco cessation supports the use of behavioural support combined with pharmacotherapy to improve quit rates.

NHS Stop Smoking Services offer behavioural support alongside pharmacotherapy and have been shown to significantly improve quit rates. You can self-refer to local services or ask your GP for a referral. Your GP or pharmacist can advise on the most suitable cessation approach for your circumstances.

NRT products deliver nicotine without the additional toxic compounds found in tobacco, making them considerably less harmful than continued tobacco use, though the evidence base for this specifically in the context of liver disease is indirect.

What other lifestyle factors affect fatty liver disease?

Diet, alcohol, physical activity and body weight all strongly influence MASLD; a Mediterranean-style diet, regular exercise and reducing alcohol alongside stopping tobacco offer the greatest benefit.

Fatty liver disease is strongly influenced by diet, physical activity, alcohol consumption and body weight, and addressing these factors alongside stopping tobacco use gives the liver the best chance of recovery. MASLD is closely linked to metabolic syndrome, a cluster of conditions including central obesity, type 2 diabetes, high blood pressure and raised triglycerides. Managing these underlying conditions is central to NICE and British Society of Gastroenterology (BSG) guidance on MASLD.

Diet plays a particularly important role. A diet high in ultra-processed foods, refined carbohydrates, added sugars and saturated fats promotes hepatic fat accumulation. Conversely, a Mediterranean-style diet, rich in vegetables, legumes, wholegrains, oily fish and olive oil, has good evidence for reducing liver fat and improving metabolic markers.^[3][4] Reducing or eliminating alcohol is also essential, as alcohol is independently hepatotoxic and compounds the damage caused by metabolic fatty liver disease.

Regular physical activity, including both aerobic exercise and resistance training, has been shown to reduce liver fat even without significant weight loss. The UK Chief Medical Officers' Physical Activity Guidelines, reflected in NHS guidance, recommend at least 150 minutes of moderate-intensity activity per week for adults.^[9][10] Weight loss of 7 to 10 per cent of body weight is associated with meaningful improvements in liver histology, including reductions in inflammation and fibrosis, as supported by BSG and EASL guidance on MASLD management.

For people seeking structured support with weight management, a range of options exists, including NHS Tier 3 weight management services, though access depends on local Integrated Care Board (ICB) commissioning criteria and referral pathways. Where clinically appropriate, pharmacological treatment may also be considered. Bolt Pharmacy is a GPhC-registered UK online pharmacy offering online weight-management consultations, with prescriber review and pharmacist support, where a range of treatment options may be considered based on individual clinical need. Addressing all modifiable risk factors together, rather than in isolation, produces the greatest benefit for liver health.

When should you see a doctor about your liver health?

See your GP if you use chewing tobacco and have liver symptoms or metabolic risk factors; they can arrange liver function tests and a FIB-4 score to assess fibrosis risk in line with NICE guidance.

You should see your GP if you use or have used chewing tobacco and have any symptoms that may suggest liver disease, or if you have known risk factors such as obesity, type 2 diabetes or heavy alcohol use. Fatty liver disease is often silent in its early stages, meaning many people have no symptoms at all. When symptoms do occur, they can include persistent fatigue, discomfort or a dull ache in the upper right abdomen, and, in more advanced disease, jaundice (yellowing of the skin or whites of the eyes), swelling of the abdomen or legs, and easy bruising.

Your GP can arrange blood tests to check liver function, including alanine aminotransferase (ALT) and aspartate aminotransferase (AST), which are elevated when liver cells are damaged. The FIB-4 score, calculated from routine blood results, is used in UK primary care as an initial non-invasive assessment of liver fibrosis risk, in line with NICE NG49 and BSG guidance on abnormal liver blood tests and MASLD pathways.^[15] An ultrasound scan may also be arranged; it can suggest the presence of steatosis but is not a precise tool for quantifying liver fat content.

If your GP identifies signs of significant fibrosis or cirrhosis, or if your results are uncertain, you may be referred to a hepatologist or gastroenterologist for further assessment, which could include an enhanced liver fibrosis (ELF) test, a FibroScan (transient elastography) or, in some cases, a liver biopsy.

Seek urgent medical attention by calling 999 or going to your nearest A and E department if you experience sudden severe abdominal pain, vomiting blood, or pass black tarry stools, as these may indicate a serious liver complication. For non-urgent concerns that cannot wait for a GP appointment, NHS 111 can provide advice. Suspected adverse reactions to any medicine can be reported via the MHRA Yellow Card scheme at yellowcard.mhra.gov.uk.

Scientific References

1. A multisociety Delphi consensus statement on new fatty liver disease nomenclature.
2. Understanding the evolving nomenclature of steatotic liver disease.
3. Mediterranean diet for the management of metabolic dysfunction-associated steatotic liver disease (MASLD).
4. The impact of dietary interventions on liver health biomarkers in individuals with MASLD: a systematic literature review and meta-analysis of randomised controlled trials.
5. Cadmium: toxicological overview.
6. Structured Exercise Interventions and Hepatic-Metabolic Outcomes in Adults with MASLD: A Narrative Review of Randomised Controlled Trials.
7. Effects of Resistance Exercise and Whey Protein Supplementation on Irisin Levels in Patients with MASLD Under a Calorie-Restricted Diet.
8. Smokeless tobacco: South Asian communities. Public Health Guideline PH39.
9. Physical activity guidelines: UK Chief Medical Officers' report.
10. Physical activity guidelines for adults aged 19 to 64.
11. Tobacco: preventing uptake, promoting quitting and treating dependence. NICE Guideline NG209.
12. Bupropion SR for smoking cessation.
13. Zyban 150 mg prolonged release tablets – Summary of Product Characteristics.
14. Review of the evidence that pH is a determinant of nicotine dosage from oral use of smokeless tobacco.
15. Alcoholic fatty liver disease [DAP59] – Protocol (FIB-4 as first-line fibrosis assessment).

Frequently Asked Questions